NCT05664893 2026-04-15
CALHYS
Centre Antoine Lacassagne
Phase 1/2 Withdrawn
Clinical Trials
10 trialsNCT07164976 2026-04-13
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Nagoya City University
Phase 1/2 Recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT03090165 2026-01-02
Ribociclib and Bicalutamide in AR+ TNBC
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT05319873 2025-05-13
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT02555189 2024-05-13
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Completed
NCT02494921 2022-08-31
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
University of California, San Francisco
Phase 1/2 Completed
NCT02657343 2022-08-01
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT03913234 2022-05-10
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Yonsei University
Phase 1/2 Unknown
NCT02607124 2020-11-05
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Terminated